Sestrin2 as a potential therapeutic target for cardiovascular diseases.


Journal

Pharmacological research
ISSN: 1096-1186
Titre abrégé: Pharmacol Res
Pays: Netherlands
ID NLM: 8907422

Informations de publication

Date de publication:
09 2020
Historique:
received: 17 04 2020
revised: 17 05 2020
accepted: 31 05 2020
pubmed: 9 6 2020
medline: 6 7 2021
entrez: 8 6 2020
Statut: ppublish

Résumé

Sestrin2 is a cysteine sulfinyl reductase that plays crucial roles in regulation of antioxidant actions. Sestrin2 provides cytoprotection against multiple stress conditions, including hypoxia, endoplasmic reticulum (ER) stress and oxidative stress. Recent research reveals that upregulation of Sestrin2 is induced by various transcription factors such as p53 and activator protein 1 (AP-1), which further promotes AMP-activated protein kinase (AMPK) activation and inhibits mammalian target of rapamycin protein kinase (mTOR) signaling. Sestrin2 triggers autophagy activity to reduce cellular reactive oxygen species (ROS) levels by promoting nuclear factor erythroid 2 (NF-E2)-related factor 2 (Nrf2) activation and Kelch-like ECH-associated protein 1 (Keap1) degradation, which plays a pivotal role in homeostasis of metabolic regulation. Under hypoxia and ER stress conditions, elevated Sestrin2 expression maintains cellular homeostasis through regulation of antioxidant genes. Sestrin2 is responsible for diminishing cellular ROS accumulation through autophagy via AMPK activation, which displays cardioprotection effect in cardiovascular diseases. In this review, we summarize the recent understanding of molecular structure, biological roles and biochemical functions of Sestrin2, and discuss the roles and mechanisms of Sestrin2 in autophagy, hypoxia and ER stress. Understanding the precise functions and exact mechanism of Sestrin2 in cellular homeostasis will provide the evidence for future experimental research and aid in the development of novel therapeutic strategies for cardiovascular diseases.

Identifiants

pubmed: 32505836
pii: S1043-6618(20)31298-6
doi: 10.1016/j.phrs.2020.104990
pii:
doi:

Substances chimiques

Cardiovascular Agents 0
NF-E2-Related Factor 2 0
Nuclear Proteins 0
SESN2 protein, human 0
TOR Serine-Threonine Kinases EC 2.7.11.1
AMP-Activated Protein Kinases EC 2.7.11.31

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

104990

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Auteurs

Anbo Gao (A)

Institute of Pharmacy and Pharmacology, Hengyang Medical School, University of South China, Hengyang 421002, Hunan, People's Republic of China; Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, University of South China, Hengyang 421002, Hunan, People's Republic of China.

Feng Li (F)

Medical Shcool, Hunan University of Chinese Medicine, Changsha 410000, Hunan, People's Republic of China.

Qun Zhou (Q)

Hunan Province Key Laboratory for Antibody-Based Drug and Intelligent Delivery System, School of Pharmaceutical Sciences, Hunan University of Medicine, Huaihua 418000, Hunan, People's Republic of China. Electronic address: 51281656@qq.com.

Linxi Chen (L)

Institute of Pharmacy and Pharmacology, Hengyang Medical School, University of South China, Hengyang 421002, Hunan, People's Republic of China; Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, University of South China, Hengyang 421002, Hunan, People's Republic of China; Hunan Provincial Key Laboratory of Tumor Microenvironment Responsive Drug Research, Hunan Provincial Science and Technology Department, 28 Western Changshen Road, Hengyang 421002, Hunan, People's Republic of China. Electronic address: lxchen6@126.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH